| Margaret M Higgins, MD | |
|
12605 E 16th Ave, Aurora, CO 80045-2545 | |
| (303) 724-2712 | |
| Not Available |
| Full Name | Margaret M Higgins |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 8 Years |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811359250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | R4092 (Kentucky) | Secondary |
| 208800000X | Urology | DR0065719 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Luke's South Hospital | Overland park, KS | Hospital |
| Saint Luke's East Hospital | Lees summit, MO | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Urologic Associates Inc | 7618133778 | 13 |
| Advanced Urologic Associates Inc | 7618133778 | 13 |
News Archive
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.
A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.
While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
The National Institutes of Health has awarded a prestigious Program Project Grant totaling more than $8.5 million over five-years to San Diego State University to better understand how the heart heals and ways stem cells can help the heart repair itself.
› Verified 2 days ago
| Entity Name | Advanced Urologic Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801389267 PECOS PAC ID: 7618133778 Enrollment ID: O20200409001825 |
News Archive
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.
A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.
While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
The National Institutes of Health has awarded a prestigious Program Project Grant totaling more than $8.5 million over five-years to San Diego State University to better understand how the heart heals and ways stem cells can help the heart repair itself.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Margaret M Higgins, MD 12631 East 17th Ave, Mail Stop C319, Aurora, CO 80045-5602 Ph: (303) 724-2712 | Margaret M Higgins, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (303) 724-2712 |
News Archive
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.
A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer (even those with low-risk tumours) will die within 15 years. The results were published today in the New England Journal of Medicine.
While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
The National Institutes of Health has awarded a prestigious Program Project Grant totaling more than $8.5 million over five-years to San Diego State University to better understand how the heart heals and ways stem cells can help the heart repair itself.
› Verified 2 days ago
Dr. Janine L Oliver, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-1800 | |
Dr. Michael Anthony Avallone, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Brian Flynn, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Granville L Lloyd, MD Urology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, University Of Colorado Hospital, Aurora, CO 80045 Phone: 720-848-0000 | |
Vijaya Vemulakonda, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Brian Thomas Caldwell, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Box 463, Aurora, CO 80045 Phone: 720-777-1234 | |
Eric Christian Ballon-landa, MD Urology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |